Oncology News | pharmaphorum

News

CRUK tests drug combo for advanced pancreatic cancer

Cancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in advanced pancreatic cancer as part of its Combinations Alliance.<

News

After years of delays, NICE backs Celgene's Revlimid in firs...

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with

News

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J unveils top pipeline prospects, with main focus on cance...

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans to file 10 major drugs between now and 2023.

News

Merck and Pfizer's Bavencio approved for renal cell carcinom...

Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of

News

FDA advisors reject one Daiichi Sankyo cancer drug, back ano...

Daiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for its leukaemia drug quizartinib, but recommended pexidartinib for a rare tumour.

CRUK tests drug combo for advanced pancreatic cancer

After years of delays, NICE backs Celgene's Revlimid in firs...

Roche and AbbVie’s Venclexta approved in CLL

J&J unveils top pipeline prospects, with main focus on cance...

Merck and Pfizer's Bavencio approved for renal cell carcinom...

FDA advisors reject one Daiichi Sankyo cancer drug, back ano...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks